Amicus Therapeutics ApS: Financial statements 2025
CVR: 39359340
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Amicus Therapeutics ApS (CVR 39359340) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. That is a decrease of 27.5% compared with the year before. Equity in the 2025 report amounted to DKK 424,641. The solvency ratio was 10%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,441,140
- Profit/Loss
- DKK 115,004
- Equity
- DKK 424,641
- Total Assets
- DKK 4,230,541
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 1.4 mio. | 115 t. | 425 t. | 1 |
| 2024 | - | 2 mio. | 16 t. | 310 t. | 1 |
| 2023 | - | 1.7 mio. | 52 t. | 355 t. | 1 |
| 2022 | - | 1.6 mio. | 54 t. | 303 t. | 1 |
| 2021 | - | 644 t. | 19 t. | 249 t. | 1 |
Official annual report
How creditworthy is Amicus Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Amicus Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK 1,987,087, and the net result was DKK 16,475.
About Amicus Therapeutics ApS
Amicus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Richard Gideon Morris. The board consists of Richard Gideon Morris (chair), Brian Keogh and Steven John Green. The company is owned by Amicus Therapeutics UK Ltd.. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. Equity in the 2025 report amounted to DKK 424,641.